South Korean CrystalGenomics Targets U.S. And Europe For Osteoarthritis Product
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's CrystalGenomics plans to conduct a Phase IIb or Phase III osteoarthritis safety and efficacy study for its next-generation NSAID CG100649, possibly in Asia next year following positive results from its Phase IIa clinical study in 25 European clinical centers in Germany, Hungary and Ukraine